Circulating non-coding RNAs as biomarkers in coronary artery disease

  • Aleksa Petković “Dr Dragisa Misovic – Dedinje” Clinical Hospital Centre, Biochemistry Diagnostics, Department of Laboratory Diagnostics
  • Sanja Erceg University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry
  • Jelena Munjas University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry
  • Ana Ninić University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry
  • Miron Sopić University of Belgrade - Faculty of Pharmacy, Department of Medical Biochemistry
Keywords: coronary artery disease, non-coding RNA, miRNA, lncRNA, biomarkers


Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis involves an interplay of different pathological mechanisms, such as progressive inflammation, abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries, creating an ischemic environment for the heart muscle, which finally leads to clinical complications, such as acute myocardial infarction. Currently, there are no biomarkers that could predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in extracellular fluids can originate from different cells, circulating ncRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following paper, we provide current insights into potential molecular mechanisms by which miRNAs and lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in diagnosis and prognosis of disease.


World Health Organization (WHO) [Internet]. News. Item; c2021 [cited 2021 Dec 1]. Available from: who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019

Institute of Public Health of Serbia “Dr Milan Jovanovic Batut” [Internet]. INCIDENCE AND MORTALITY OF ACUTE CORONARY SYNDROME IN SERBIA 2019. Serbian Acute Coronary Syndrome Registry. Report number 14; c2021 [cited 2021 Dec 1]. Available from:

Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241.

National Heart, Lung and Blood Institute (NIH) [Internet]. Health topics. Atherosclerosis; c2021 [cited 2021 Dec 25]. Available from:

Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019;400(6):711-32.

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.

Sakharkar MK, Chow VT, Kangueane P. Distributions of exons and introns in the human genome. In Silico Biol. 2004;4(4):387-93.

Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304-51.

Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, et al. Noncoding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018;39(29):2704.

Munjas J, Sopic M, Stefanovic A, Kosir R, Ninic A, Joksic I, et al. Non-coding RNAs in preeclampsia – molecular mechanisms and diagnostic potential. Int J Mol Sci. 2021;22:10652.

Costa F. Non-coding RNAs – Meet thy masters. Bioessays. 2010;32:599-608.

Caselli C, Prontera C, Liga R, De Graaf MA, Gaemperli O, Lorenzoni V, et al. Effect of coronary atherosclerosis and myocardial ischemia on plasma levels of high-sensitivity troponin T and NT-proBNP in patients with stable angina. Arterioscler Thromb Vasc Biol. 2016;36(4):757-64.

Wu N, Ma F, Guo Y, Li X, Liu J, Qing P, et al. Association of N-terminal pro-brain natriuretic peptide with the severity of coronary artery disease in patients with normal left ventricular ejection fraction. Chin Med J. 2014;127(4):627-32.

O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.

Tanase DM, Gosav EM, Ouatu A, Badescu MC, Dima N, Ganceanu-Rusu AR, et al. Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI). Life. 2021;11(10):1057.

Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019;47(7):3353-64.

Melak T, Baynes HW. Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review. Ejifcc. 2019;30(2):179.

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-24.

Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056-60.

Dexheimer PJ, Cochella L. MicroRNAs: from mechanism to organism. Front Cell Dev Biol. 2020;8:409.

Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene. 2010;29(15):2302-8.

Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110(3):483-95.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513-8.

Soufi-Zomorrod M, Hajifathali A, Kouhkan F, Mehdizadeh M, Rad SM, Soleimani M. MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs. Tumor Biol. 2016;37(7):9527-34.

Pegoraro V, Cudia P, Baba A, Angelini C. MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy. Neurol Sci. 2020;41(10):2953-60.

Li T, Li X, Feng Y, Dong G, Wang Y, Yang J. The role of matrix metalloproteinase-9 in atherosclerotic plaque instability. Mediators Inflamm. 2020;2020:3872367.

Meng N, Li Y, Zhang H, Sun XF. RECK, a novel matrix metalloproteinase regulator. Histol. Histopathol. 2008;23(8):1003-10.

Fan X, Wang E, Wang X, Cong X, Chen X. MicroRNA-21 is a unique signature associated with coronary plaque instability in humans by regulating matrix metalloproteinase-9 via reversion-inducing cysteine-rich protein with Kazal motifs. Exp Mol Pathol. 2014;96(2):242-9.

Sheedy FJ. Turning 21: induction of miR-21 as a key switch in the inflammatory response. Front Immunol. 2015;6:19.

Basatemur GL, Jørgensen HF, Clarke MC, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol. 2019;16(12):727-44.

Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460(7256):705-10.

Tian FJ, An LN, Wang GK, Zhu JQ, Li Q, Zhang YY, et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res. 2014;103(1):100-10.

Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Investig. 2012;122(11):4190-202.

Zhou J, Li YS, Nguyen P, Wang KC, Weiss A, Kuo YC, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell–secreted microRNA-126: role of shear stress. Circ Res. 2013;113(1):40-51.

Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81.

Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368-76.

Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci. 2008;105(5):1516-21.

Chiu A, Chan WK, Cheng SH, Leung CK, Choi CH. Troponin-I, myoglobin, and mass concentration of creatine kinase-MB in acute myocardial infarction. Qjm. 1999 Dec 1;92(12):711-8.

Wang F, Long G, Zhao C, Li H, Chaugai S, Wang Y, et al. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med. 2013;11(1):1-9.

Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659-66.

Zhang L, Chen X, Su T, Li H, Huang Q, Wu D, et al. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis. 2015;7(3):303.

Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51(5):872-5.

Huang S, Chen M, Li L, He MA, Hu D, Zhang X, et al. Circulating MicroRNAs and the occurrence of acute myocardial infarction in Chinese populations. Circ Cardiovasc Genet. 2014;7(2):189-98.

Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277(2):260-71.

Gacoń J, Kabłak-Ziembicka A, Stępień E, Enguita FJ, Karch I, Derlaga B, et al. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2016;74(3):280-8.

Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su LX, Guo D, et al. Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PloS One. 2015;10(5):e0123477.

Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PloS One. 2015;10(12):e0145930.

Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc. 2014;3(6):e001249.

Dong J, Liang YZ, Zhang J, Wu LJ, Wang S, Hua Q, Yan YX. Potential role of lipometabolism-related microRNAs in peripheral blood mononuclear cells as biomarkers for coronary artery disease. J Atheroscler Thromb. 2017;24(4):430-41.

Matsumoto S, Sakata Y, Nakatani D, Suna S, Mizuno H, Shimizu M, et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem Biophys Res Commun. 2012;427(2):280-4.

He F, Lv P, Zhao X, Wang X, Ma X, Meng W, et al. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014;394(1):137-44.

Schonrock N, Harvey R, Mattick J. Long Noncoding RNAs in Cardiac Development and Pathophysiology. Circ Res. 2012;111:1349-1362.

Wu H, Yang L, Chen L. The Diversity of Long Noncoding RNAs and Their Generation. Trends Genet. 2017;33:540-552.

Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118.

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47-62.

Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genomics Proteomics Bioinformatics. 2016;14(2):73-80.

Li Y, Liu L. LncRNA OIP5-AS1 Signatures as a Biomarker of Gestational Diabetes Mellitus and a Regulator on Trophoblast Cells. Gynecol Obstet Invest. 2021;86(6)1-9.

Yang S, Yang H, Luo Y, Li Y, Zhou Y, Hu B. Long non-coding RNAs in neurodegenerative diseases. Neurochem Int. 2021;148:105096.

Guo F, Tang C, Li Y, Liu Y, Lv P, Wang W, Mu Y. The interplay of Lnc RNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κBsignalling pathway. J Cell Mol Med. 2018; 22(10):5062-75.

Xu B, Xu Z, Chen Y, Lu N, Shu Z, Tan X. Genetic and epigenetic associations of ANRIL with coronary artery disease and risk factors. BMC Medical Genom. 2021;14(1):1-12.

Fang J, Pan Z, Wang D, Lv J, Dong Y, Xu R, et al. Multiple non-coding ANRIL transcripts are associated with risk of coronary artery disease: a promising circulating biomarker. J Cardiovasc Transl Res. 2021;14(2):229-37.

Yan ZS, Zhang NC, Li K, Sun HX, Dai XM, Liu GL. Upregulation of long non-coding RNA myocardial infarction-associated transcription is correlated with coronary artery stenosis and elevated inflammation in patients with coronary atherosclerotic heart disease. Kaohsiung J Med Sci. 2021;37(12):1038-1047.

Gao Y, Wu F, Zhou J, Yan L, Jurczak MJ, Lee HY, et al. The H19/let-7 doublenegative feedback loop contributes to glucose metabolism in muscle cells. Nucleic Acids Res. 2014;42:13799–81.

Yao Y, Xiong G, Jiang X, Song T. The overexpression of lncRNA H19 as a diagnostic marker for coronary artery disease. Rev Assoc Med Bras. 2019;65:110–7.

Liao B, Chen R, Lin F, Mai A, Chen J, Li H, et al. Long noncoding RNA HOTTIP promotes endothelial cell proliferation and migration via activation of the Wnt/β-catenin pathway. J Cell Biochem. 2018;(3):2797-805.

Hu YW, Yang JY, Ma X, Chen ZP, Hu YR, Zhao JY, et al. A lincRNADYNLRB2-2/GPR119/GLP-1R/ABCA1 - dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res. 2014;55:681–97.

Zhang L, Zhou C, Qin Q, Liu Z, Li P. LncRNA LEF1-AS1 regulates the migration and proliferation of vascular smooth muscle cells by targeting miR-544a/PTEN axis. J Cell Biochem. 2019;120(9):14670-8.

Xu Y, Shao B. Circulating lncRNA IFNG-AS1 expression correlates with increased disease risk, higher disease severity and elevated inflammation in patients with coronary artery disease. J Clin Lab Anal. 2018;32(7):e22452.

Shang J, Li Q, Zhang J, Yuan H. FAL1 regulates endothelial cell proliferation in diabetic arteriosclerosis through PTEN/AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22:6492–9.

Hu YW, Guo FX, Xu YJ, Li P, Lu ZF, McVey DG, et al. Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN. J Clin Investig. 2019;129(3):1115-28.

Wang XM, Li XM, Song N, Zhai H, Gao XM, Yang YN. Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction. Biomed Pharmacother. 2019;118:109208.

Zhang Z, Gao W, Long QQ, Zhang J, Li YF, Yan JJ, et al. Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep. 2017; 7(1);1-9.

Yang Y, Cai Y, Wu G, Chen X, Liu Y, Wang X, et al. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci. 2015;129(8):675-85.

Li M, Wang LF, Yang XC, Xu L, Li WM, Xia K, et al. Circulating long noncoding RNA LIPCAR acts as a novel biomarker in patients with ST-segment elevation myocardial infarction. Med Sci Monit. 2018;24:5064.

Lv F, Liu L, Feng Q, Yang X. Long non-coding RNA MALAT1 and its target microRNA-125b associate with disease risk, severity, and major adverse cardiovascular event of coronary heart disease. J Clin Lab Anal. 2021;35(4):e23593.

Review articles